List view / Grid view




Eisai bewildered as IQWIG fails to recognise OS benefit of liposarcoma drug

5 September 2016 | By Niamh Louise Marriott, Digital Content Producer

n study 309, the pivotal phase III trial on which the indication approval was based, eribulin demonstrated a significant survival advantage in advanced liposarcoma; patients treated with eribulin compared to those treated with dacarbazine, a longstanding, established and internationally accepted treatment option, benefited from a median 7.2 month increase in…